Faculty of Medicine
Permanent URI for this communityhttps://repository.ukim.mk/handle/20.500.12188/14
Browse
3 results
Search Results
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Molecular and Immunohistochemical Biomarkers in Colorectal Carcinoma - A Single Center Study(Walter de Gruyter GmbH, 2025-06); - Some of the metrics are blocked by yourconsent settings
Item type:Publication, DUAL HER2 BLOCKADE WITH TRASTUZUMAB AND PERTUZAMB IN HER2- POSITIVE BREAST CANCER: SINGLE CENTER REAL WORLD DATA(Macedonian Association of Anatomists, 2020-12-30); ; ; Agents targeting the human epidermal growth factor receptor 2 (HER2) have improved outcomes of advanced HER2-positive breast cancer with durable responses. We evaluated therapy with trastuzumab and pertuzumab in early and metastatic HER2-positive breast cancer patients. In this paper we discuss the practicalities of treating patients with this combination with a particular focus on treatment in the single center setting. We retrospectively identifed patients on adjuvant and frst-line anti-HER2 therapy at The University Clinic of Radiotherapy and Oncology Skopje for at least 1 year from 2019 to 2020. Demographics, treatments and adverse events were recorded. The combination of pertuzumab–trastuzumab has established efficacy in patients with HER2‐positive advanced/metastatic breast cancer. Management of treatment related side‐effects such as diarrhea, febrile neutropenia and neuropathy typically include dose reduction or switching taxane. Specific patients with poorer tolerance of chemotherapy such may require particular management strategies.The roles of trastuzumab and pertuzumab are now very well established in the frst-line setting; identifying predictors of long-term response to these would be important in selecting which patients might beneft from entry into future clinical trials assessing the long-term beneft of these newer agents in addition. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, CORRELATION BETWEEN HER2 AND EBV EXPRESSION IN GASTRIC CARCINOMA(Macedonian Association of Anatomists, 2020); ; ; Hadzi-Mancev DIntroduction: The understanding of the etiopathogenesis and the molecular basis of gastric carcinoma will facilitate the development of novel molecular target therapies, which interfere with different signal cascades involved in cellular proliferation, differentiation and survival. The aim of this paper was to determine the correlation between HER2 and EBV expression in patients with gastric carcinomas. Material and methods: Eighty patients with gastric carcinoma surgically treated were included in the study. Data of HER2 protein expression were obtained from the archived histopathological reports of the Institute of Pathology in Skopje. For detection of EBV, immunostainings were performed on tumor tissue and the peripheral nontumor gastric mucosa. Results: The results of this study confirmed a significant association between HER2 and EBV expression (p=0.041). The value of the Spearman correlation coefficient (R = - 0.258) indicated a negative, indirect connection of HER2 and EBV expression, which was confirmed as statistically significant (p = 0.02). The HER2 expression in gastric carcinomas was significantly associated with EBV expression, and the expression of HER2 was significantly more common in EBV negative cancers.